Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma’s Eric Pauwels, who’s launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.
Report: Dendreon looking for buyer
October 28, 2013
7:35 pm
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
Business briefs: Sanofi, GlaxoSmithKline, AllTrials
August 8, 2013
4:24 pm
Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals